Skip to Content

Cocrystal Pharma Inc COCP

Morningstar Rating
$1.46 +0.01 (0.39%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

COCP is trading at a 69% discount.
Price
$1.44
Fair Value
$7.37
Uncertainty
Extreme
1-Star Price
$81.27
5-Star Price
$7.22
Economic Moat
Xqgsm
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if COCP is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$1.45
Day Range
$1.401.46
52-Week Range
$1.333.29
Bid/Ask
$1.42 / $1.45
Market Cap
$14.80 Mil
Volume/Avg
6,179 / 14,189

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first-and best-in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
12

Valuation

Metric
COCP
Price/Earnings (Normalized)
Price/Book Value
0.48
Price/Sales
Price/Cash Flow
Price/Earnings
COCP

Financial Strength

Metric
COCP
Quick Ratio
15.74
Current Ratio
16.74
Interest Coverage
Quick Ratio
COCP

Profitability

Metric
COCP
Return on Assets (Normalized)
−48.70%
Return on Equity (Normalized)
−51.27%
Return on Invested Capital (Normalized)
−52.19%
Return on Assets
COCP
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRBzhjq$541.4 Bil
VRTX
Vertex Pharmaceuticals IncVpymdl$110.3 Bil
REGN
Regeneron Pharmaceuticals IncXfmbntr$108.4 Bil
MRNA
Moderna IncRxwml$37.2 Bil
ARGX
argenx SE ADRTlqz$23.7 Bil
BNTX
BioNTech SE ADRGwfq$21.7 Bil
ALNY
Alnylam Pharmaceuticals IncCkjdmw$19.5 Bil
BMRN
Biomarin Pharmaceutical IncHwdqjlh$16.7 Bil
RPRX
Royalty Pharma PLC Class AByffzgq$13.7 Bil
INCY
Incyte CorpHfggph$13.5 Bil

Sponsor Center